The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.
about
Evolving spectrum of HIV-associated rheumatic syndromesRheumatoid arthritis in patients with HIV: management challengesAssessment and management of musculoskeletal disorders among patients living with HIV.Attenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation.Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.Persistent immune activation in chronic HIV infection: do any interventions work?Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.HLA-DR+ CD38+ CD4+ T lymphocytes have elevated CCR5 expression and produce the majority of R5-tropic HIV-1 RNA in vivo.Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.CD38 Expression in a Subset of Memory T Cells Is Independent of Cell Cycling as a Correlate of HIV Disease Progression.Inflammation, immune activation, and cardiovascular disease in HIV.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Immunotherapeutic restoration in HIV-infected individuals.Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV-infected individuals.Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity.Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety.HIV as a Cause of Immune Activation and Immunosenescence.
P2860
Q26781402-D1ACCCA5-6C4D-4380-B656-BEA5BCA02B1DQ28075624-2A76BD42-F47E-422A-B897-2B4FA6D825E0Q30239955-EB35327A-17C6-4306-9B8D-7B415490AF8DQ34300102-AE79842A-E70F-439D-A6D5-7031DCBB10D8Q34315572-17FB7DA8-3883-47EF-AB46-66B6B65965C4Q34456352-D4D49B4F-48C8-4C59-92F9-0568D18A1227Q34851102-85772F49-215C-461A-B06C-534B5AA2F263Q34975716-F86F37C2-63AC-422A-9AE7-45A2222DCE16Q35382501-1B0B6AF3-BA00-4D2F-A261-A41D4D00ED14Q36344908-84661E60-BAEF-458A-9BCC-D80DFE3591F4Q36731541-F19646F9-13E9-4F06-9751-48C5309B3374Q36957752-55B4D3DE-AB06-4D38-AAA3-5211B504561EQ37418140-E5D45045-3E68-4264-802B-54AACCA8D6CDQ37842335-5F05BC26-E54F-4A2C-ACF9-ADE3C8B826F4Q37851515-0E3A3E5B-8534-44B2-94FA-FC7E5705D375Q38812233-9BF2DDD4-C0EB-4BEC-8DCA-8C236092F7A4Q40296944-BB65EB06-3304-41C7-94E9-0B1A325C9A59Q41333604-3010A3A9-C32D-4919-869A-40D52139A082Q47151081-7C359169-337E-4381-B5EB-B1265B8FCCD5
P2860
The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The effect of leflunomide on c ...... n HIV-1-infected participants.
@ast
The effect of leflunomide on c ...... n HIV-1-infected participants.
@en
type
label
The effect of leflunomide on c ...... n HIV-1-infected participants.
@ast
The effect of leflunomide on c ...... n HIV-1-infected participants.
@en
prefLabel
The effect of leflunomide on c ...... n HIV-1-infected participants.
@ast
The effect of leflunomide on c ...... n HIV-1-infected participants.
@en
P2093
P2860
P1433
P1476
The effect of leflunomide on c ...... in HIV-1-infected participants
@en
P2093
Catherine Rehm
Jeanette Higgins
Joseph W Adelsberger
Judith M Starling
Mary DeGrezia
Rebecca DerSimonian
Sarah W Read
P2860
P304
P356
10.1371/JOURNAL.PONE.0011937
P407
P577
2010-08-03T00:00:00Z